RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Rhea-AI Summary

RAPT Therapeutics, Inc. (Nasdaq: RAPT), focused on immunology and oncology therapies, announced a poster presentation for FLX475, its lead oncology drug candidate, at the 2023 ASCO annual meeting scheduled for June 2-6, 2023. The poster titled "Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer" will be presented on June 3, 2023, from 8:00 a.m. to 11:00 a.m. ET. The abstract associated with the presentation will be released on May 25, 2023. RAPT is advancing two key drug candidates, RPT193 and FLX475, aimed at treating inflammatory diseases and cancer, respectively, showcasing their commitment to addressing significant unmet medical needs.

Positive

• Upcoming presentation at ASCO could enhance investor interest and visibility.
• Focus on FLX475 may strengthen RAPT's position in the oncology sector.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it will present a poster on FLX475, its lead oncology drug candidate, at the 2023 American Society of Clinical Oncology (ASCO) annual meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.

Presentation details:
Title:	Clinical and Biological Activity of FLX475, an Oral CCR4 Antagonist, in Advanced Cancer
Session Title:	Developmental Therapeutics—Immunotherapy
Session Date and Time:	Saturday, June 3, 2023; 8:00 a.m. - 11:00 a.m. ET
Abstract Number:	2625

The abstract will be released on Thursday, May 25, 2023 at 5:00 p.m. ET on meetings.asco.org.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary discovery and development engine, the company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, RPT193 and FLX475, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of inflammation and cancer, respectively. The company is also pursuing a range of targets that are in the discovery stage of development.

Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com

Media Contact:
Aljanae Reynolds
areynolds@wheelhouselsa.com

FAQ

What is the significance of RAPT's presentation at ASCO 2023?

RAPT's presentation on FLX475 at ASCO 2023 could boost investor interest and showcase their advancements in oncology therapies.

When will RAPT Therapeutics present the FLX475 poster?

RAPT will present the FLX475 poster on June 3, 2023, from 8:00 a.m. to 11:00 a.m. ET.

What is FLX475 being developed for?

FLX475 is an oral CCR4 antagonist being developed for advanced cancer treatment.

When will the abstract for the FLX475 presentation be released?

The abstract will be released on May 25, 2023, at 5:00 p.m. ET.